title: Use of allogeneic tissue to treat infective valvular disease: Has everything been said?
authors.affiliation: Cardiac Surgery Center, Cardiologique du Nord de Saint-Denis, Paris, France. Electronic address: francesconappi2@gmail.com.
authors.forename: Francesco
authors.initials: F
authors.lastname: Nappi
authors.affiliation: Department of Cardiothoracic Surgery, Golden Jubilee National Hospital, Glasgow, United Kingdom; Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.
authors.forename: Cristiano
authors.initials: C
authors.lastname: Spadaccio
authors.affiliation: Department of Cardiovascular Surgery, Hôpital de la Salpétrière, Paris, France.
authors.forename: Christophe
authors.initials: C
authors.lastname: Acar
mesh_terms: D064591:Allografts; D001021:Aortic Valve / Q000503:physiopathology / Q000601:surgery*; D001705:Bioprosthesis; D000066491:Clinical Decision-Making; D004696:Endocarditis / Q000175:diagnosis / Q000503:physiopathology / Q000601:surgery*; D006350:Heart Valve Prosthesis; D019918:Heart Valve Prosthesis Implantation / Q000009:adverse effects / Q000295:instrumentation*; D006801:Humans; D008943:Mitral Valve / Q000503:physiopathology / Q000601:surgery*; D011474:Prosthesis Design; D020127:Recovery of Function; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome